What is Angiocrine Bioscience?
Angiocrine Bioscience is a biotechnology enterprise dedicated to the development of advanced cellular therapies. At the core of its operations is the proprietary E-CEL technology, a platform engineered to facilitate the repair, regeneration, and restoration of damaged tissues and organs. Unlike traditional pharmaceutical approaches that often manage symptoms, Angiocrine focuses on the underlying biological mechanisms of tissue health, aiming to provide curative outcomes for patients suffering from complex degenerative conditions.
The company operates at the intersection of molecular biology and regenerative medicine, targeting high-unmet-need patient populations. By utilizing specialized cellular constructs, the firm seeks to redefine the standard of care in regenerative health, effectively bridging the gap between laboratory research and clinical application. Their market position is defined by a commitment to high-impact therapeutic innovation, supported by a robust intellectual property portfolio.
How much funding has Angiocrine Bioscience raised?
Angiocrine Bioscience has raised a total of $2.3M across 2 funding rounds:
Debt
$150K
Stock/Share Issuance
$2.1M
Debt (2020): $150K with participation from PPP
Stock/Share Issuance (2025): $2.1M, investors not publicly disclosed
Key Investors in Angiocrine Bioscience
Undisclosed Investor
An undisclosed institutional partner participating in the most recent round of strategic financing.
PPP
Public-Private Partnership
What's next for Angiocrine Bioscience?
With the recent influx of capital, Angiocrine Bioscience is well-positioned to accelerate its clinical trial pipeline and scale its manufacturing capabilities for E-CEL therapies. The strategic focus will likely shift toward expanding the therapeutic indications for their platform, potentially targeting a broader range of organ-specific pathologies. As the company matures, the emphasis will remain on navigating regulatory pathways and establishing strategic partnerships to facilitate the commercialization of their regenerative assets.
Investors and industry stakeholders will be monitoring the firm's progress in upcoming clinical milestones, which will serve as the primary catalyst for future valuation growth. The ability to demonstrate sustained efficacy in human trials will be the definitive factor in determining the company's long-term impact on the global biotechnology landscape.
